Ipsen S.a. Sponsored Adr News, Ipsen S.a. Sponsored Adr Quote, IPSEY Quote

Ipsen S.a. Sponsored Adr (OP:IPSEY) Delayed: 28.76 +0.04 (0.14%)

Prev. Close

$28.72

Open

$28.76

52 Wk High

$17.79

52 Wk Low

$13.01

Day High

$28.76

Day Low

$28.76

P/E

N/A

EPS

$0.00

Volume

1,330

Friends, Peers and Foes (?): IPN, IPN:FP, BXB, SREN, BVNRY (more...)

Apr 2, 2024 07:00 AM Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Feb 13, 2024 04:08 PM Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA
Dec 7, 2023 01:00 AM Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
Nov 20, 2023 02:44 AM Jefferies Downgrades Ipsen SA (IPN:FP) (IPSEY) to Hold
Nov 13, 2023 07:00 AM Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Oct 23, 2023 01:00 AM Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
Oct 11, 2023 11:17 AM Ipsen SA (IPN:FP) (IPSEY) PT Raised to EUR122 at RBC Capital
Sep 4, 2023 01:00 AM Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
Sep 1, 2023 01:00 AM Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
Aug 16, 2023 03:32 PM US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

Entities mentioned with IPSEY